Merck & Co Extending Allergy Interests With House Dust Mite Filing

Merck & Co has submitted a BLA for what is likely to be its third sublingual allergy immunotherapy (SLIT) tablet to become available in the US, one developed to treat house dust mite (HDM) allergies, an important cause of allergic rhinitis and allergic asthma that might boost so-far underwhelming US sales of its new allergy products.